Dexamethasone acetate
- Generic Name
- Dexamethasone acetate
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31FO6
- CAS Number
- 1177-87-3
- Unique Ingredient Identifier
- K7V8P532WP
- Background
Commonly known as decadron, dexamethasone acetate is a glucocorticosteroid previously marketed in the USA for the treatment of inflammatory respiratory, allergic, autoimmune, and other conditions. Developed in 1957, dexamethasone is structurally similar to other corticosteroids such as hydrocortisone and prednisolone. Dexamethasone acetate has largely been replaced by dexamethasone phosphate and continues to be administered for a large variety of inflammatory conditions.
Recently, dexamethasone has been a drug of interest in the treatment of COVID-19. In a June 16 2020 press release highlighting early results of a clinical trial, Randomized Evaluation of COVID-19 Therapy (RECOVERY), it was reported that dexamethasone reduced COVID-19 deaths by approximately one-fifth and one-third in patients on oxygen therapy and mechanical ventilation, respectively. Dexamethasone was therefore recommended as a life-saving treatment for COVID-19 patients experiencing severe respiratory symptoms.
- Associated Conditions
- Candida Albicans Vulvovaginitis, Dermatitis, Fungal Vaginal Infections
- Associated Therapies
- Corticosteroid therapy
Anti-inflammatory Steroids in the Prevention of Tooth Sensitivity
- Conditions
- Inflammation
- Interventions
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Universidade Federal Fluminense
- Target Recruit Count
- 70
- Registration Number
- NCT02956070
Interest of Cryotherapy or Cortisone Aerosol Therapy in Early Post-operative Swallowing Disorders Following Total Thyroidectomy
- Conditions
- ThyroidectomyPost-operative Swallowing Disorders
- Interventions
- Procedure: thyroidectomyOther: cryotherapy
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Centre Hospitalier Universitaire Dijon
- Target Recruit Count
- 240
- Registration Number
- NCT02855866
- Locations
- 🇫🇷
CHU Dijon Bourgogne, Dijon, France
Evaluation of Preoperative Submucosal Dexamethasone in Third Molar Surgery
- Conditions
- Impacted Third Molar Tooth
- Interventions
- Procedure: Third molar surgery
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 60
- Registration Number
- NCT02837614
The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Hui Bu
- Target Recruit Count
- 200
- Registration Number
- NCT02588196
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Precursor-B Acute Lymphoblastic LeukemiaLymphoblastic LymphomaLymphomaLeukemia
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2018-06-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT02419469
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Prolongation of Pain Free Time by the Use of Dexamethasone in Peripheral Nerve Blockade
- Conditions
- Interscalene BlockShoulder ArthroscopyDexamethasoneLow Volume Regional Anesthesia
- Interventions
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2014-06-30
- Lead Sponsor
- Landesklinikum Sankt Polten
- Target Recruit Count
- 109
- Registration Number
- NCT02178449
- Locations
- 🇦🇹
Landesklinikum Sankt Pölten, Sankt Pölten, Lower Austria, Austria
Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 460
- Registration Number
- NCT01916252
- Locations
- 🇪🇸
Hospital Univ. Fundación de Alcorcón, Alcorcón, Spain
🇪🇸Hospital de León, León, Spain
🇪🇸Hospital Universitario de Guadalajara, Guadalajara, Spain
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
- Conditions
- T-Cell LymphomaRelapsed T-Cell LymphomaRefractory T-Cell Lymphoma
- Interventions
- Drug: PEG-L-asparaginase
- First Posted Date
- 2013-06-17
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT01878708
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)
- Conditions
- NeuroblastomaOpsoclonus Myoclonus Syndrome
- Interventions
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 102
- Registration Number
- NCT01868269
- Locations
- 🇫🇷
Chu Amiens, Amiens, France
🇦🇹St. Anna Kinderkrebsforschung e.V. CHILDREN'S CANCER RESEARCH INSTITUTE, Wien, Austria
🇫🇷Chu de Bicetre, Le Kremlin-Bicêtre, LE Kremlin Bicetre, France
Comparison of Efficacy of Nebulizing Budesonide and Intravenous Dexamethasone Before Extubation on Prevention of Post-extubation Complications in Intensive Care Unit Patients
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Saeed Abbasi
- Target Recruit Count
- 90
- Registration Number
- NCT01854515
- Locations
- 🇮🇷
Alzahra University Hospital, Isfahan, Iran, Islamic Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.